Literature DB >> 17275330

Remedial strategies in structural proteomics: expression, purification, and crystallization of the Vav1/Rac1 complex.

Alexei Brooun1, Scott A Foster, Jill E Chrencik, Ellen Y T Chien, Anand R Kolatkar, Markus Streiff, Paul Ramage, Hans Widmer, Gisbert Weckbecker, Peter Kuhn.   

Abstract

The signal transduction pathway involving the Vav1 guanine nucleotide exchange factor (GEF) and the Rac1 GTPase plays several key roles in the immune response mediated by the T cell receptor. Vav1 is also a unique member of the GEF family in that it contains a cysteine-rich domain (CRD) that is critical for Rac1 binding and maximal guanine nucleotide exchange activity, and thus may provide a unique protein-protein interface compared to other GEF/GTPase pairs. Here, we have applied a number of remedial structural proteomics strategies, such as construct and expression optimization, surface mutagenesis, limited proteolysis, and protein formulation to successfully express, purify, and crystallize the Vav1-DH-PH-CRD/Rac1 complex in an active conformation. We have also systematically characterized various Vav1 domains in a GEF assay and Rac1 in vitro binding experiments. In the context of Vav1-DH-PH-CRD, the zinc finger motif of the CRD is required for the expression of stable Vav1, as well as for activity in both a GEF assay and in vitro formation of a Vav1/Rac1 complex suitable for biophysical and structural characterization. Our data also indicate that the isolated CRD maintains a low level of specific binding to Rac1, appears to be folded based on 1D NMR analysis and coordinates two zinc ions based on ICP-MS analysis. The protein reagents generated here are essential tools for the determination of a three dimensional Vav1/Rac1 complex crystal structure and possibly for the identification of inhibitors of the Vav1/Rac1 protein-protein interaction with potential to inhibit lymphocyte activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17275330      PMCID: PMC1892187          DOI: 10.1016/j.pep.2006.10.027

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  34 in total

1.  Global conformational rearrangements during the activation of the GDP/GTP exchange factor Vav3.

Authors:  Oscar Llorca; Ernesto Arias-Palomo; José L Zugaza; Xosé R Bustelo
Journal:  EMBO J       Date:  2005-03-10       Impact factor: 11.598

2.  NMR screening and crystal quality of bacterially expressed prokaryotic and eukaryotic proteins in a structural genomics pipeline.

Authors:  Rebecca Page; Wolfgang Peti; Ian A Wilson; Raymond C Stevens; Kurt Wüthrich
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

3.  Lck regulates Vav activation of members of the Rho family of GTPases.

Authors:  J Han; B Das; W Wei; L Van Aelst; R D Mosteller; R Khosravi-Far; J K Westwick; C J Der; D Broek
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis.

Authors:  Martin E Fernandez-Zapico; Natalia C Gonzalez-Paz; Ellen Weiss; Doris N Savoy; Julian R Molina; Rafael Fonseca; Thomas C Smyrk; Suresh T Chari; Raul Urrutia; Daniel D Billadeau
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

Review 5.  Vav-family proteins in T-cell signalling.

Authors:  Victor L J Tybulewicz
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

Review 6.  GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors.

Authors:  Kent L Rossman; Channing J Der; John Sondek
Journal:  Nat Rev Mol Cell Biol       Date:  2005-02       Impact factor: 94.444

7.  The crystal structure of RhoA in complex with the DH/PH fragment of PDZRhoGEF, an activator of the Ca(2+) sensitization pathway in smooth muscle.

Authors:  Urszula Derewenda; Arkadiusz Oleksy; Andra S Stevenson; Justyna Korczynska; Zbigniew Dauter; Andrew P Somlyo; Jacek Otlewski; Avril V Somlyo; Zygmunt S Derewenda
Journal:  Structure       Date:  2004-11       Impact factor: 5.006

8.  Recognition and activation of Rho GTPases by Vav1 and Vav2 guanine nucleotide exchange factors.

Authors:  Jongyun Heo; Roopa Thapar; Sharon L Campbell
Journal:  Biochemistry       Date:  2005-05-03       Impact factor: 3.162

9.  Protein production by auto-induction in high density shaking cultures.

Authors:  F William Studier
Journal:  Protein Expr Purif       Date:  2005-05       Impact factor: 1.650

10.  Solution structure of a cysteine rich domain of rat protein kinase C.

Authors:  U Hommel; M Zurini; M Luyten
Journal:  Nat Struct Biol       Date:  1994-06
View more
  6 in total

1.  Application of protein engineering to enhance crystallizability and improve crystal properties.

Authors:  Zygmunt S Derewenda
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-04-21

2.  Structural basis of guanine nucleotide exchange mediated by the T-cell essential Vav1.

Authors:  Jill E Chrencik; Alexei Brooun; Hui Zhang; Irimpan I Mathews; Greg L Hura; Scott A Foster; J Jefferson P Perry; Markus Streiff; Paul Ramage; Hans Widmer; Gary M Bokoch; John A Tainer; Gisbert Weckbecker; Peter Kuhn
Journal:  J Mol Biol       Date:  2008-05-17       Impact factor: 5.469

Review 3.  The role of protein structural analysis in the next generation sequencing era.

Authors:  Wyatt W Yue; D Sean Froese; Paul E Brennan
Journal:  Top Curr Chem       Date:  2014

4.  On the mechanism of autoinhibition of the RhoA-specific nucleotide exchange factor PDZRhoGEF.

Authors:  Meiying Zheng; Tomasz Cierpicki; Ko Momotani; Mykhaylo V Artamonov; Urszula Derewenda; John H Bushweller; Avril V Somlyo; Zygmunt S Derewenda
Journal:  BMC Struct Biol       Date:  2009-05-21

5.  International research networks in viral structural proteomics: again, lessons from SARS.

Authors:  Bruno Canard; Jeremiah S Joseph; Peter Kuhn
Journal:  Antiviral Res       Date:  2007-11-01       Impact factor: 5.970

6.  Crucial structural role for the PH and C1 domains of the Vav1 exchange factor.

Authors:  Jonathan Rapley; Victor L J Tybulewicz; Katrin Rittinger
Journal:  EMBO Rep       Date:  2008-05-30       Impact factor: 8.807

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.